OUR SCIENCE

Seed-and-Boost®: a new mechanism
for durable T-cell therapy

Highly selective T cell engagers to expand T cell therapies in vivo.

Cell Therapies for Solid Tumors are limited by fundamental operational and biological constraints

  • Need for very high starting T cell dose
  • Need for preconditioning and/or systemic cytokine administration
  • Lack of T cell persistence / durability
  • T cell exhaustion and dysfunction in TME
  • Moderate short-term efficacy

 

  • Historic efforts have limited utility:
    • Armoring
    • Gene editing
    • Combination with check point inhibitors
    • Exogenous IL-2
    • Novel manufacturing methods

A novel T cell engager to selectively boost therapeutic T cells through TCR-level specificity

Selective in vivo expansion of tumor-specific T cells enabling persistent and strong anti-tumor responses

Leveraging clinical validation of T cell expansion and the Boost mechanism in patients

  • Booster molecule clinically tested and shown to expand T cells in humans

 

  • Presents opportunity to:
    • Significantly reduce T cell starting dose, lower costs and offer faster turn-around times
    • Drive in vivo expansion in patients, on demand
    • Avoid preconditioning and systemic cytokine administration
    • Deliver deeper and more durable responses